Claims

What is claimed is:

1. An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2.

2. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 2, or the complement thereof.

3. A probe for use in identifying a patient at risk for progression into the malignant phenotype comprising the nucleotide sequence of SEQ ID NO: 2, or the complement thereof, or the labeled nucleotide sequence of SEQ ID NO: 2, or the complement thereof.

4. The probe of claim 3, wherein the label is a fluorescent dye molecule, a radioisotope, a chemiluminescent molecule, or an enzyme.

5. A method for detecting whether a patient is at risk for progression into glioblastoma multiforme comprising,

   a) providing a sample from a patient;

   b) adding a labeled probe comprising the nucleotide sequence of SEQ ID NO:2 to the sample or performing PCR analysis using SEQ ID NO: 5 and SEQ ID NO: 6;

   c) analyzing levels of mRNA bound with the probe;

   d) treating a control sample according to the method to assess the level of mRNA in a control sample; wherein the presence of increased levels of mRNA expression in the sample in an amount higher than the control sample indicates risk for progression into glioblastoma multiforme.

6. A kit for use in detecting whether a patient is at risk for progression into glioblastoma multiforme comprising nucleotide sequence probes of SEQ ID NO:2 and instructions for use.

7. The kit of claim 6, further comprising reagents and components for use in performing assays.

8. A kit for use in detecting whether a patient is at risk for progression into glioblastoma multiforme comprising nucleotide sequence probes of SEQ ID NO: 5 and SEQ ID NO: 6 and instructions for use.

9. The kit of claim 8, further comprising reagents and components necessary to use SEQ ID NO: 5 and SEQ ID NO: 6 as primers for PCR amplification reaction.